Rationale for BRC-001, a high CBD plant extract, to reduce joint pain during aromatase inhibitor treatment
At least half a million women in the United States rely on aromatase inhibitors for breast cancer treatment. Aromatase inhibitors are administered to postmenopausal women with estrogen-receptor positive cancer to reduce levels of circulating estrogen. Side effects of aromatase inhibitors include joint pain (arthralgia) which can lead some women to discontinue treatment and increase the risk of cancer recurrence. Existing therapies are not effective in achieving the long-term pain management benefits that allow all patients to stay on therapy. There is no approved treatment for aromatase inhibitor-induced arthralgia (AIIA).
How our investigational therapy can potentially benefit patients
Certain cannabinoids have been shown to decrease inflammation in joint tissues and reduce pain associated with joint inflammation. BRC-001 is designed to mitigate the inflammatory actions and co-morbidities of aromatase-inhibitors.
